
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
The positive outlook for IQVIA Holdings is supported by a 5% increase in RFP flow across all market segments, reflecting strong demand, particularly in the EBP segment, alongside a projected robust funding environment for 2024 that is expected to enhance deal volumes. Additionally, the company's forward-looking plans to allocate $2 billion in capital for mergers and acquisitions and share repurchases in 2025, along with a 5.5% growth in NTM backlog at constant FX, indicate a favorable trajectory for revenue growth, especially within the R&D Services segment where growth is anticipated to accelerate. Furthermore, the combination of pent-up demand and a solid new business pipeline underscores the potential for meaningful revenue expansion as the market stabilizes.
Bears say
IQVIA Holdings Inc. is experiencing significant challenges due to prolonged COVID-19 impacts, increased interest expenses, and a declining biopharma funding environment, all of which have adversely affected investor sentiment and earnings per share (EPS) growth since the first quarter of 2022. The company's backlog has remained flat, influenced by foreign exchange headwinds that prompted a substantial downward revision of previously reported figures, indicating potential weaknesses in future revenue generation. Additionally, gross margins showed a sequential decline of 60 basis points, compounded by unfavorable revenue mixes and rising interest rates, contributing to anticipated lower earnings and a compression of stock multiples.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares